Editas Medicine, Inc.

EDIT Healthcare Biotechnology

Editas Medicine, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 25.4% from fiscal 2024. In the quarter to June 2026, revenue grew 232.3%, EPS grew 76.2% and free cash flow grew 40.7%, each against the same quarter a year earlier.

2.45 0.30 −10.91%
Market cap
$422.3M
P/E
0.0×
Fwd P/E
−2.7×
Dividend yield
—
F-score
2/9
Altman Z
−13.39
Beneish M
−2.46
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— 5 5 2 3 3 2 4 2 2
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
1.62 3.28 2.25 2.17 12.28 6.84 (1.28) (0.67) (7.30) (13.39)
P/S ratio
90.70 100.81 33.55 72.09 45.29 70.28 29.40 9.70 3.24 4.49
Altman Z″-Score (non-manufacturers)
0.42 1.69 1.59 0.95 1.07 3.11 (3.54) (4.23) (14.20) (29.91)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
(40.14) (55.20) 807.45 36.08 (102.47) (51.91) (13.71) (34.09) (2.06) (5.00)
Beneish M-Score
(3.16) (0.54) (2.01) 16.96 4.42 (4.56) 18.81 (0.16) 7.05 (2.46)
P/B ratio
4.08 6.65 4.54 5.64 10.44 3.24 1.61 2.17 0.78 6.67
Price to Tangible BV
4.08 6.65 4.54 5.64 10.44 3.24 1.61 2.17 0.78 6.67
EV/Sales
65.89 79.27 23.01 51.40 41.21 51.98 13.58 5.98 (4.11) 1.67
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.53 0.00
EV/Operating CF
(7.94) (115.56) (16.08) (25.95) (20.79) (8.11) (1.51) (3.54) 0.63 (0.41)
EV/FCF
(7.42) (94.95) (14.58) (22.58) (20.00) (7.73) (1.48) (3.41) 0.61 (0.41)
Quick Ratio
5.60 8.99 10.28 7.63 7.01 10.67 5.81 5.27 3.71 3.50
Current Ratio
5.66 9.05 10.44 7.74 7.20 10.82 5.94 5.39 3.75 3.54
Net Debt/EBITDA
1.57 2.52 3.05 3.31 3.07 2.68 1.56 1.92 1.07 0.94
Debt/Assets
15.31% 8.96% 7.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.26 0.16 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.03 0.05 0.08 0.04 0.17 0.04 0.03 0.15 0.08 0.15
Operating CF/Net income
0.52 0.08 0.42 0.30 1.55 0.85 0.80 0.86 0.89 1.03
Capex/Depreciation
(2.89) (0.76) (1.45) (2.14) (1.81) (1.19) (0.73) (3.80) (490.33) (0.08)
Interest Coverage
1,567.55 (122.63) 346.73 (1,028.63) 8.29 (113.75) 174.75 — (114.68) (25.93)
ROE
(377.64%) (70.22%) (49.50%) (53.65%) (35.36%) (40.65%) (48.22%) (43.17%) (98.10%) (198.14%)
ROA
(51.37%) (39.95%) (27.71%) (28.79%) (21.45%) (30.80%) (36.99%) (30.24%) (56.40%) (60.61%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% (224.39%) (860.78%) (406.90%) 0.00% 0.00%
Return on Tangible Assets
(50.00%) (35.92%) (29.00%) (32.25%) (30.94%) (40.31%) (70.60%) (52.90%) (104.64%) (132.07%)
Average Days of Receivables
5.31 18.05 0.34 7.43 24.33 3.82 95.27 47.59 183.73 136.70
Research and Development Expense of Revenue
941.33% 605.76% 283.85% 471.96% 174.13% 557.89% 887.57% 227.40% 616.60% 222.00%
Selling, General and Administrative Expense of Revenue
764.28% 367.88% 172.25% 314.43% 74.48% 298.24% 358.69% 89.16% 222.77% 123.16%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
280.32% 170.19% 83.28% 132.69% 25.52% 169.90% 148.61% 25.34% 66.28% 24.68%
Graham Net Nets
0.17 0.12 0.18 0.15 0.06 0.21 0.35 0.25 0.78 0.03
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(17.78%) (8.68%) (10.24%) (9.08%) (2.85%) (10.73%) (38.03%) (20.54%) (226.77%) (92.20%)
Free Cash Flow Yield
(9.78%) (0.83%) (4.71%) (3.16%) (4.55%) (9.57%) (31.31%) (18.06%) (209.54%) (91.01%)
Revenue per Share
0.19 0.34 0.68 0.41 1.55 0.38 0.29 1.03 0.39 0.46
Operating CF per Share
(1.56) (0.23) (0.97) (0.81) (3.07) (2.42) (2.58) (1.74) (2.55) (1.86)
Capex per Share
(0.11) (0.05) (0.10) (0.12) (0.12) (0.12) (0.06) (0.06) (0.11) 0.00
Free Cash Flow per Share
(1.67) (0.28) (1.07) (0.93) (3.19) (2.54) (2.64) (1.80) (2.66) (1.87)
Cash per Share
5.75 8.16 7.83 9.15 6.86 7.39 5.01 4.25 3.28 1.65
Shareholders Equity per Share
4.18 5.16 5.01 5.25 6.72 8.19 5.25 4.60 1.63 0.31
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.18 5.16 5.01 5.25 6.72 8.19 5.25 4.60 1.63 0.31
Free Cash Flow
(53.72) (11.46) (50.42) (46.73) (186.99) (171.78) (181.45) (136.90) (219.11) (165.58)
Working Capital
154.10 295.49 338.88 403.88 360.88 460.43 296.64 277.61 212.09 117.65
Capital Expenditures
(3.47) (2.04) (4.72) (6.06) (7.15) (7.98) (4.10) (4.72) (8.83) (0.34)
Net Current Asset Value
92.61 167.02 190.55 217.40 240.07 383.47 203.11 190.77 82.00 4.65
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.53 0.00
Capex to Sales
0.57 0.15 0.15 0.30 0.08 0.31 0.21 0.06 0.27 0.01
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.03 0.07 0.08 0.26 0.28 0.39 0.36 0.10 0.00 1.24
Cash ROIC
(15.13%) (2.01%) (7.91%) (6.49%) (23.50%) (16.31%) (25.74%) (20.37%) (54.21%) (95.20%)
Accounts Receivable Turnover
10.94 35.80 90.09 91.66 28.06 8.09 7.28 10.19 2.44 2.58
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — — — 0.00 0.00 — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — — — 0.00 0.00 — — —
Average Receivables
0.55 0.38 0.35 0.22 3.23 3.16 2.71 7.67 13.23 15.72
Average Payables
3.01 4.33 4.67 5.59 6.13 5.73 7.28 8.89 6.88 4.05
Average Assets
189.27 301.22 396.82 464.64 540.74 625.04 595.90 506.74 420.37 264.06
Average Common Equity
25.75 171.34 222.12 249.30 328.01 473.61 457.16 354.89 241.69 80.78

Fold the line items

Columns are period end dates